Cytokinetics (CYTK) CEO Robert Blum Exercises Options, Sells 7,500 Shares

What Happened
Robert I. Blum, President & CEO and a director of Cytokinetics (CYTK), exercised stock options and sold shares on 2026-08-10. The filing shows he acquired 7,500 shares by exercising options at $10.60 per share (cost $79,500) and sold 7,500 shares in an open-market transaction at $76.76 per share (gross proceeds $575,700). The report also lists a related derivative entry for 7,500 shares at $0.00 marked as disposed.

Key Details

• Transaction date: 2026-08-10
• Exercise: 7,500 shares at $10.60 (total paid $79,500) — coded M (option exercise/conversion)
• Sale: 7,500 shares sold at $76.76 (total proceeds $575,700) — coded S (open market sale)
• Additional derivative line: 7,500 shares at $0.00 listed as disposed (file shows this as a derivative conversion/surrender)
• Shares owned after transaction: Not specified in the provided filing excerpt
• Footnotes: Some shares are held in The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust (F1, F2)
• Timeliness: Filing dated 2026-08-10 for transactions on 2026-08-10; no late filing indicated in the excerpt

Context
This appears to be a cashless exercise pattern: options were exercised and an equal number of shares were sold the same day. For retail investors, exercises followed by immediate sales are often routine liquidity actions (not necessarily a directional vote on the company). The $0.00 derivative disposal line typically reflects shares surrendered or converted as part of the exercise/sale mechanics (e.g., to cover option costs or tax withholding) as reported on the Form 4.